Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Gynecologic 1

Conditions

Carcinoma, Hepatocellular 17Stomach Neoplasms 8Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Rectal Neoplasms 5Neoplasm Metastasis 4Triple Negative Breast Neoplasms 3Pancreatic Neoplasms 3Nasopharyngeal Carcinoma 3Esophageal Neoplasms 3Uterine Cervical Neoplasms 2Solid Tumor 2Recurrence 2Lung Neoplasms 2Esophageal Squamous Cell Carcinoma 2Endometrial Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Spinocerebellar Degenerations 1Small Cell Lung Carcinoma 1Resectable NSCLC 1Ovarian Neoplasms 1Neuroblastoma 1Neoplasms, Unknown Primary 1Neoplasms 1Metastatic Gastroesophageal Junction Adenocarcinoma 1Meningeal Carcinomatosis 1MSI-H 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

pembrolizumab 27Oxaliplatin 24Paclitaxel 22Fluorouracil 21Carboplatin 18Leucovorin 16Cisplatin 16Capecitabine 16Radiotherapy 15Nivolumab 12Drug Therapy 12Radiation 10Trastuzumab 9Surgical Procedures, Operative 9Immunotherapy 8Magnetic Resonance Spectroscopy 7Esophagectomy 7Blood Specimen Collection 7Taxes 6durvalumab 5Surveys and Questionnaires 5Specimen Handling 5Radiotherapy, Intensity-Modulated 5Irinotecan 5Immune Checkpoint Inhibitors 5Docetaxel 5Bevacizumab 5tislelizumab 4Ramucirumab 4Fluorodeoxyglucose F18 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Esophageal Neoplasms × sintilimab × 1 year × Clear all
NCT05357846 2026-04-30

PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)

Sun Yat-sen University

Phase 3 Recruiting
422 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT07306663 2025-12-29

ESO-Nanjing7

Jiangsu Cancer Institute & Hospital

Phase 3 Active not recruiting
242 enrolled
Gastrointestinal

Esophageal Neoplasms

NCT05383482 2025-11-17

Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1

Laekna Limited

Phase 1/2 Completed
22 enrolled
GastrointestinalGynecologic

Uterine Cervical Neoplasms, Esophageal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡